Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge

: Cutaneous melanoma (CM) is the fourth tumor in frequency, and that whose incidence increases faster. In half of the cases, CM arises from pre-existing nevi. CM is a highly heterogeneous tumor, whose degree of differentiation varies among different hosts, and such heterogeneity is probably based on the accumulation of mutations that determine transitions from normal melanocytic stem cells (cid:1) mutated benign melanocytic stem cells (cid:1) malignant melanocytic stem cells (cid:1) clonogenic melanocytic cells. These populations may express different antigens and would therefore trigger the proliferation of different T and B cell clones. Early diagnosis is the clue for the cure of CM; when visceral metastatic disease is established, the prognosis is somber. This is especially so since CM is quite resistant to chemotherapy, and some of the reasons for such resistance will be discussed here. However, CM has proved to be sensitive to immunological effectors, although the mechanism of such sensitivity is still being investigated. These effectors range from therapeutic vaccines, in vitro expanded cytotoxic lymphocytes, cytokines, and monoclonal antibodies. Finally, we will discuss new therapeutic approaches that include the combination of immune modulators and vaccines which are being assayed in light of recent tumor immunology research.

• Publication year

  2010

• Venue

  Current Cancer Therapy Reviews

• Publication date

  2010-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157339410791698232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐lasting cross‐presentation of tumor antigen in human DC

  2009cited by this paper
• Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.

  2009cited by this paper
• Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53

  2009cited by this paper
• Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

  2009cited by this paper
• Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity1

  2008cited by this paper
• Epistatic connections between microphthalmia‐associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders

  2008cited by this paper
• Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou

  2008cited by this paper
• Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.

  2008cited by this paper
• Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.

  2008cited by this paper
• Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma

  2008cited by this paper
• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

  2008cited by this paper
• Involvement of dynein and spectrin with early melanosome transport and melanosomal protein trafficking.

  2008cited by this paper
• A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression

  2008cited by this paper
• PAX3 expression in primary melanomas and nevi

  2008cited by this paper
• The epidermal and dermal origin of melanocytic tumors: theoretical considerations based on epidemiologic, clinical, and histopathologic findings.

  2008cited by this paper
• Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

  2008cited by this paper
• Identification of cells initiating human melanomas

  2008cited by this paper
• Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

  2008cited by this paper
• Vascular normalization in Rgs5-deficient tumours promotes immune destruction

  2008cited by this paper
• Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2008cited by this paper
• Expression patterns of MITF during human cutaneous embryogenesis: evidence for bulge epithelial expression and persistence of dermal melanoblasts

  2008cited by this paper
• Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma

  2008cited by this paper
• Downregulation of CCN3 expression as a potential mechanism for melanoma progression

  2008cited by this paper
• Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

  2008cited by this paper
• MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

  2008cited by this paper
• Efficient tumour formation by single human melanoma cells

  2008cited by this paper
• Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma

  2008cited by this paper
• Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma

  2008cited by this paper
• Temozolomide induces senescence but not apoptosis in human melanoma cells

  2007cited by this paper
• Vaccine therapy for melanoma: current status and future directions.

  2007cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Melanomas arising from naevi and de novo melanomas — does origin matter?

  2007cited by this paper
• Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

  2007cited by this paper
• Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential.

  2007cited by this paper
• SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation

  2007cited by this paper
• Ancient evolutionary origin of the neural crest gene regulatory network.

  2007cited by this paper
• Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.

  2007influential reference
• Increased expression of stem cell markers in malignant melanoma

  2007cited by this paper
• Human skin pigmentation: melanocytes modulate skin color in response to stress

  2007cited by this paper
• Drug resistance in melanoma: new perspectives.

  2007cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes

  2007cited by this paper
• Chordate ancestry of the neural crest: new insights from ascidians.

  2007cited by this paper
• Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.

  2007cited by this paper
• Development of the neural crest: achieving specificity in regulatory pathways.

  2006cited by this paper
• Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.

  2006cited by this paper
• Age‐related prevalence of dermoscopy patterns in acquired melanocytic naevi

  2006cited by this paper
• Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

  2006cited by this paper
• c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage*

  2006cited by this paper
• Advances in Brief AHumanCanalicularMultispecificOrganicAnionTransporter ( cMOAT ) GeneIs Overexpressed in Cisplatin-resistant Human Cancer Cell Lines with Decreased Drug Accumulation '

  2006cited by this paper
• Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

  2006cited by this paper
• CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1

  2006cited by this paper
• Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity

  2006cited by this paper
• A Phase I Study of an Allogeneic Cell Vaccine (VACCIMEL) With GM-CSF in Melanoma Patients

  2006cited by this paper
• Melanoma, a tumor based on a mutant stem cell?

  2006cited by this paper
• High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.

  2006cited by this paper
• First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

  2006cited by this paper
• Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

  2006cited by this paper
• New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1

  2006cited by this paper
• Tumorigenesis and Neoplastic Progression Galectin-3 Expression Correlates with Apoptosis of Tumor-Associated Lymphocytes in Human Melanoma Biopsies

  2006cited by this paper
• Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

  2005cited by this paper
• Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

  2005cited by this paper
• Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

  2005cited by this paper
• ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.

  2005cited by this paper
• Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression

  2005cited by this paper
• A tumorigenic subpopulation with stem cell properties in melanomas.

  2005cited by this paper
• Pax3 functions at a nodal point in melanocyte stem cell differentiation

  2005cited by this paper
• Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche

  2005cited by this paper
• Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A

  2005cited by this paper
• Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells

  2005cited by this paper
• Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.

  2004cited by this paper
• Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

  2004cited by this paper
• Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.

  2004cited by this paper
• Melanocytes of fetal dermis - studies with anti-HMB-45 antibody.

  2004cited by this paper
• Update on the systemic treatment of malignant melanoma.

  2004cited by this paper
• Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma

  2004cited by this paper
• Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• Melanocyte‐specific expression of dopachrome tautomerase is dependent on synergistic gene activation by the Sox10 and Mitf transcription factors

  2004cited by this paper
• Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.

  2004cited by this paper
• The appearance, density and distribution of melanocytes in human embryonic and fetal skin revealed by the anti-melanoma monoclonal antibody, HMB-45

  2004cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1

  2004cited by this paper
• Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

  2003cited by this paper
• MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.

  2003cited by this paper
• Systemic chemotherapy in the treatment of malignant melanoma

  2003cited by this paper
• Curing metastatic cancer: lessons from testicular germ-cell tumours

  2003cited by this paper
• Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.

  2003cited by this paper
• Homozygous and heterozygous inheritance of PAX3 mutations causes different types of Waardenburg syndrome

  2003cited by this paper
• Loss of PTEN promotes tumor development in malignant melanoma.

  2003cited by this paper
• ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility.

  2003cited by this paper
• Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo

  2003cited by this paper
• Cutaneous melanomas associated with nevi.

  2003cited by this paper
• Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma 1

  2003cited by this paper
• Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF.

  2002cited by this paper
• Dominant role of the niche in melanocyte stem-cell fate determination

  2002cited by this paper

• No citing papers are available for this paper.